Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy

Patent metadata

Field	Value
Publication number	US-9364494-B2
Application number	US-68194308-A
Country	US
Kind code	B2
Filing date	Oct 10, 2008
Priority date	Oct 10, 2007
Publication date	Jun 14, 2016
Grant date	Jun 14, 2016

Abstract

The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject.

First claim

The invention claimed is:

1. A method for treating pancreatic cancer comprising administering intratumorally or orthotopically to a pancreatic tumor in a patient:
(i) at least one nucleic acid sequence encoding for a somatostatin 2 receptor protein (sst2) comprising the amino acid sequence SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5;
(ii) at least one nucleic acid sequence encoding for a deoxycytidine kinase protein (dck) comprising the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8;
(iii) at least one nucleic acid sequence encoding for a uridine monophosphate kinase protein (umk) comprising the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 9, and
(iv) gemcitabine, wherein said nucleic acids are expressed, and wherein expression of said nucleic acids and administration of gemcitabine results in recession of said pancreatic tumor in the patient.

2. The method of claim 1 , wherein said administering inhibits metastasis of said pancreatic tumor in the patient.

3. The method of claim 1 , wherein said patient is a human.

4. The method of claim 1 , wherein the at least one nucleic acid sequence encoding dck in (ii) is the amino acid sequence set for in SEQ ID NO: 2 and the at least one nucleic acid sequence encoding umk in (iii) is the amino acid sequence SEQ ID NO: 3, and wherein the nucleic acids of (ii) and (iii) are administered simultaneously.

5. The method of claim 4 , wherein the at least one nucleic acid of (ii) and (iii) are linked by a nucleic acid encoding a cleavable Foot-and-Mouth-Disease virus (FMDV) 2 A peptide, thereby encoding the amino acid sequence set forth in SEQ ID NO: 10.

6. The method of claim 1 , wherein the at least one nucleic acids of (i)-(iii) are present within one expression vector.

7. The method of claim 6 , wherein the one expression vector comprise a nucleic acid having the sequence set forth in SEQ ID NO: 11.

8. The method of claim 6 , wherein said expression vector is complexed with a non-lipid cationic polyethylenimine (PEI) polymers.

9. A pharmaceutical composition comprising an expression vector comprising:
(i) at least one nucleic acid sequence encoding for a somatostatin 2 receptor protein (sst2) comprising the amino acid sequence SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5;
(ii) at least one nucleic acid sequence encoding for a deoxycytidine kinase protein (dck) comprising the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8;
(iii) at least one nucleic acid sequence encoding for a uridine monophosphate kinase protein (umk) comprising the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 9.

10. The pharmaceutical composition according to claim 9 , wherein the one expression vector comprise a nucleic acid having the sequence set forth in SEQ ID NO:11, wherein the at least one nucleic acid of (ii)-(iii) are linked by a nucleic acid encoding a cleavable Foot-and-Mouth-Disease virus (FMDV) 2 A peptide, thereby encoding the amino acid sequence set forth in SEQ ID NO: 10.

11. The pharmaceutical composition according to claim 10 , wherein said expression vector is complexed with a non-lipid cationic polyethylenimine (PEI) polymers.

12. A plasmid vector comprising one expression vector comprising a nucleic acid having the sequence set forth in SEQ ID NO:11, which comprises:
(i) at least one nucleic acid sequence encoding for a somatostatin 2 receptor protein (sst2) comprising the amino acid sequence SEQ ID NO: 1, SEQ ID NO: 4, or SEQ ID NO: 5;
(ii) at least one nucleic acid sequence encoding for a deoxycytidine kinase protein (dck) comprising the amino acid sequence SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, or SEQ ID NO: 8;
(iii) at least one nucleic acid sequence encoding for a uridine monophosphate kinase protein (umk) comprising the amino acid sequence SEQ ID NO: 3 or SEQ ID NO: 9, wherein the at least one nucleic acid of (ii)-(iii) are linked by a nucleic acid encoding a cleavable Foot-and-Mouth-Disease virus (FMDV) 2 A peptide, thereby encoding the amino acid sequence set forth in SEQ ID NO: 10.

13. The method according to claim 1 , wherein said gemcitabine is administrated at a dose of equal or less than 750 mg/m 2 per day.

Assignees

• Buscail Louis
• Tiraby Gérard
• Vernejoul Fabienne
• Susini Christiane
• Drocourt Daniel
• Inst Nat Sante Rech Med
• Cayla

Inventors

• Buscail Louis
• Tiraby Gérard
• Vernejoul Fabienne
• Susini Christiane
• Drocourt Daniel

Classifications

• A61K31/7068 Primary

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• C12Y207/04022

  UMP kinase (2.7.4.22) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K47/59

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title

• A61K38/45

  Transferases (2) · CPC title